Search
Imipenem
go.drugbank.com/drugs/DB01598ApprovedInvestigational[label] It is stable to many beta-lactamases. … Imipenem was first approved by the FDA in November 1985 as the combination product Primaxin marketed by Merck & Co.[L7628]
Mixtures: IMIPENEM E CILASTATINA SUN, IMIPENEM E CILASTATINA SUNPeramivir
go.drugbank.com/drugs/DB06614ApprovedInvestigationalDue to the poor oral bioavailability, the oral formulation of the drug was previously abandoned by Johnson and Johnson Company. … The development of peramivir has been supported by the US Department of Health and Human Services as part of the government's effort to prepare for a flu pandemic.
Atacicept
go.drugbank.com/drugs/DB06399ApprovedInvestigationalAtacicept is a recombinant fusion glycoprotein that joins the ligand-binding portion of the human TACI receptor to a modified IgG1 Fc domain, allowing it to bind and neutralize two cytokines: B cell activating … [L63797] The US FDA granted accelerated approval to atacicept-vymj on July 7, 2026, to reduce proteinuria in adults with primary IgA nephropathy at risk for disease progression.
Gefitinib
go.drugbank.com/drugs/DB00317ApprovedInvestigationalActing in a similar manner to erlotinib (marketed as Tarceva), gefitinib selectively targets the mutant proteins in malignant cells. It is marketed by AstraZeneca under the trade name Iressa. … Gefitinib (originally coded ZD1839) is a drug used in the treatment of certain types of cancer.
Categories: Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitorsPropiverine
go.drugbank.com/drugs/DB12278ApprovedOveractive bladder (OAB) is a chronic condition of the lower urinary tract characterized by urinary urgency, increased frequency of urination, and nocturia (frequent waking during the night to urinate) … The impact of OAB on quality of life is sometimes devastating, especially to elderly patients with other medical conditions [L2328].
Categories: Adrenergic alpha-1 Receptor AntagonistsBenzhydrocodone
go.drugbank.com/drugs/DB15465Approved[L4894] It was developed in an effort to reduce parenteral bioavailability of the active metabolite as a deterrent to abuse. … It was first approved by the FDA in February 2018 in combination with [acetaminophen] under the trade name Apadaz, marketed by KVK Tech and developed by KemPharm.[L7859,L7862]
Eflapegrastim
go.drugbank.com/drugs/DB15001ApprovedInvestigational[L43135] Eflapegrastim is a form of recombinant human G-CSF comprising a human G-CSF analog coupled to the Fc fragment of human IgG4 via a polyethylene glycol linker. … [A252320] They trigger signaling pathways that control the differentiation, proliferation, migration, and survival of neutrophils, thereby helping to restore depressed neutrophil counts.
Penicillium chrysogenum var. chrysogenum
go.drugbank.com/drugs/DB10439ApprovedPenicillium chrysogenum var. chrysogenum is a fungus which can provoke allergic reactions. Penicillium chrysogenum var. chrysogenum extract is used in allergenic testing.
Mixtures: Number Ten Mold Mixture, Number Ten Mold MixtureLifitegrast
go.drugbank.com/drugs/DB11611ApprovedInvestigationalThe ophthalmic solution was approved in July, 2016 under the trade name Xiidra. … It has shown to protect the corneal surface and alleviate the symptoms of dry eye syndrome with fast onset of action and well tolerated profile in both local and systemic setting [A18805].
Nitrofurantoin
go.drugbank.com/drugs/DB00698ApprovedInvestigationalVet approved[A179824] This drug is more resistant to the development of bacterial resistance because it acts on many targets at once. … [L6856,L6859,L6862] Nitrofurantoin is converted by bacterial nitroreductases to electrophilic intermediates which inhibit the citric acid cycle as well as synthesis of DNA, RNA, and protein.